Daniele
Florio
a,
Sara
La Manna
a,
Alfonso
Annunziata
b,
Ilaria
Iacobucci
bc,
Vittoria
Monaco
bc,
Concetta
Di Natale
d,
Valentina
Mollo
e,
Francesco
Ruffo
b,
Maria
Monti
bc and
Daniela
Marasco
*a
aDepartment of Pharmacy, University of Naples Federico II, 80131, Naples, Italy. E-mail: daniela.marasco@unina.it; Tel: +39-081-2532043
bDepartment of Chemical Sciences, University of Naples Federico II, 80126, Naples, Italy
cCEINGE Biotecnologie Avanzate “Franco Salvatore” S.c.a r.l., 80131, Naples, Italy
dInterdisciplinary Research Centre on Biomaterials (CRIB), Department of Ingegneria Chimica del Materiali e della Produzione Industriale (DICMAPI), University Federico II, 80125 Naples, Italy
eCenter for Advanced Biomaterials for Healthcare, Istituto Italiano di Tecnologia (IIT), Largo Barsanti e Matteucci 53, Naples 80125, Italy
First published on 22nd May 2023
Neurodegenerative diseases are often characterized by the formation of aggregates of amyloidogenic peptides and proteins, facilitating the formation of neurofibrillary plaques. In this study, we investigate a series of Ru-complexes sharing three-legged piano-stool structures based on the arene ring and glucosylated carbene ligands. The ability of these complexes to bind amyloid His-peptides was evaluated by ESI-MS, and their effects on the aggregation process were investigated through ThT and Tyr fluorescence emission. The complexes were demonstrated to bind the amyloidogenic peptides even with different mechanisms and kinetics depending on the chemical nature of the ligands around the Ru(II) ion. TEM analysis detected the disaggregation of typical fibers caused by the presence of Ru-compounds. Overall, our results show that the Ru-complexes can modulate the aggregation of His-amyloids and can be conceived as good lead compounds in the field of novel anti-aggregating agents in neurodegeneration.
As is commonly accepted, diverse mechanisms concur in neurodegenerative diseases (NDDs).3 Thus, a wide range of compounds have been explored as therapeutics.4 Among the others, transition metal complexes appeared to be good starting compounds for the development of novel neuroprotective-agents.5,6
Ruthenium-complexes are in clinical trials for the treatment of several cancers7 owing to their ability to overcome cisplatin resistance and low general toxicity,8 and recently they are being applied in NDDs.9 In a pioneering study, six Ru complexes, containing alternative chloride and aromatic ligands, revealed the capability at different extents to bind the fragment 106–126 of the prion protein, PrP106–126.10
In the context of Alzheimer's disease (AD), the PMRU-CYM0 compound (2-aminothiazolium[trans-RuCl4(2-aminothiazole)2]) was found to be effective in the modulation of Aβ1–42 aggregation with low toxicity.11
Other studies outlined that Ru-complexes bearing thiazole ligands were more able to inhibit Aβ1–42 aggregation with respect to NAMI-A (imidazolium[trans-RuCl4(1H-imidazole)(dimethyl sulfoxide-S)]), underlying the importance of secondary interaction spheres between the metallotherapeutic effect and the amyloid peptide,12,13 similarly to other Ru-complexes bearing the pyridine ligand.14 Indeed, polypyridyl ligands around the Ru-center [2,2′-bipyridine (bpy), 1,10-phenanthroline (phen), dipyrido[3,2-a:2′,3′-c]quinolino[3,2-j]phenazine (dpqp), quinoxaline (dpq), and dipyridophenazine (dppz)], were found to be efficient in the modulation of the aggregation of human islet amyloid polypeptide (hIAPP) by means of hydrophobic interactions within the metal coordination sphere. In this context, aromatic moieties promoted the disaggregation of fibrils by changing the β-sheet components and their reduction into small aggregates.15,16
Hetero-binuclear Pt–Ru complexes containing bpy and pyrazine (pyz) ligands also were shown to bind hIAPP in an enthalpy-driven process, which was mainly dependent on hydrophobic interactions and changes in the metal coordination.17
Very recently, NAMI-A exhibited a dual inhibitory effect toward α-synuclein in both aggregation and membrane interactions, which led to the mitigation of neurodegeneration and motor impairments in a rat model of Parkinson's.18
One of the most interesting features of Ru-compounds is their photo-responsiveness:19 the {[Ru(bpy)3]2+} complex revealed a sensitive, biocompatible, anti-Aβ agent that was able to destabilize the β-sheet conformation upon illumination, causing oxidative modifications of Aβ peptides and aiding the disaggregation effect.20 Similarly, the luminescent cis-[Ru(phen)2(Apy)2]2+ (Apy = 3,4-diaminopyridine) complex inhibited the aggregation and the toxicity of Aβ1–40 and its several fragments.21 It was also employed as a probe for the detection of fibrillar insulin.22,23 Similarly, the complex {[Ru(bpy)2(dpqp)]2+} has a luminescence anisotropy that allows for the tracking of the formation of amyloid oligomers at different time points for Aβ and α-synuclein,24 leading to in-cell mechanistic insights in the early stages of amyloid formation.25
Binding analyses through mass spectrometry (MS) revealed for several Ru-complexes a preferential affinity for histidine residues of the N-terminal fragment of the β-amyloid (residues 1–16), in accordance with the binding sites of other metallodrugs such as RAPTA-C and auranofin.26
In our previous studies, we investigated the ability of a series of square-planar Pt(II)-complexes to inhibit the aggregation of amyloid peptides, assumed as model amyloids.27–30 However, a five-coordinate trigonal bipyramidal glucoconjugate Pt(II) complex also was demonstrated to be an efficient inhibitor of β-amyloid fragments.31 Noticeably, the decoration of organometallic compounds with bioactive moieties able to recognize specific targets is a valid strategy to increase the biological performance of the therapeutic agents. Glycoconjugation is one of the most successful approaches32–41 because the presence of sugar residues can increase the selectivity through the Warburg effect,42 the aqueous solubility, and their biocompatibility in general.
Generally, penta- and hexa-peptides as fragments of neurodegenerative proteins were demonstrated to self-assemble, and form amyloids with various morphologies43,44 that partially recapitulate the aggregation process of larger proteins.45,46 Herein, we analyzed two different short protein fragments bearing one His residue, assumed as amyloid models, that were both uncharged at neutral pH (Table 1): (i) the fragment 27–32 of the human Bloom syndrome protein (BSP27–32),47 and (ii) the 103–108 segment of human beta-2-microglobulin that becomes 83–88 (β2m83–88), after proteolytic cleavage.43
Peptide | Sequence |
---|---|
BSP27–32 | Ac-HYFNIF-NH2 |
β2m83–88 | Ac-NHVTLS-NH2 |
Both protein fragments, not present in vivo, were identified as aggregation-prone regions (APRs) through prediction and experimental studies.48,49 The latter sequence does not display “aromatic” amino acids, such as Phe and Tyr,48 which is different from BSP27–32. These fragments present the ability to aggregate in an amyloid-way, despite their shortness and the presence of His residues as potential ligands to the ruthenium–metal center. Thus, they were assumed as amyloid models in this study, as already reported elsewhere.50,51
We evaluated the ability of three Ru-arene complexes52 containing glucosylated ligands to modulate the aggregative mechanism of amyloid models. The complexes have the general formula [Ru(η6-arene)(NHC)(X2)] (η6-arene = p-cymene (Cym) or methyl 2-benzamido-3,4,6-tri-O-acetyl-beta-D-glucoside (MBAG), NHC = N-heterocyclic carbene, containing a glucosyl and a methyl substituent, X2 = Cl− or oxalate) endowed with the typical three-legged piano-stool structure (Fig. 1).53
![]() | ||
Fig. 1 Chemical structure of the investigated Ru(II)-complexes with NHC gluco-conjugated ligands: (A) Ru-MBAG, (B) Ru-Oxa, and (C) Ru-Cym. |
Notably, these complexes recently demonstrated the ability to bind His residues of model proteins.52
The presented studies were carried out by employing a wide range of spectroscopic and biophysical techniques: we evaluated the effects of Ru-complexes on fluorescence emission profiles of ThT for both small amyloids. By means of ESI-MS assays, we evaluated the formation of adducts between amyloids and each Ru-complex, and the effects of their presence on the peptides’ conformational preferences by CD spectroscopy and on amyloid fibers through TEM analysis.
Briefly, the appropriate ruthenium arene dimer [Ru(η6-arene)(Cl2)]2 (0.55 mmol) was reacted with the silver carbene precursor Ag(NHC)Br (1.1 mmol) in 10 mL of dichloromethane for 48 hours, and protected from light. AgBr was filtered off over a pad of Celite, and the volume of the clear filtrate was reduced to 1–2 mL. The addition of diethyl ether resulted in the precipitation of the products as red-orange microcrystalline solids, washed with ether and dried under vacuum. Yields: 75–85%. The stability of the Ru-complexes was assessed by 1H-NMR and ESI-MS, by keeping the complexes over 3 days at 37 °C in aqueous solutions (H2O or NaCl, 150 mM). Complexes Ru-Cym and Ru-MBAG undergo hydrolysis of one or both chloride ligands, giving rise to an equilibrium involving the mono- and di-aqua species. Ru-Oxa is stable and no appreciable hydrolysis was observed in water nor in NaCl. Ru-MBAG also underwent gradual arene displacement, thus showing reduced stability compared to Ru-Cym and Ru-Oxa. Notably, all the complexes give rise to a slow hydrolysis of the acetyl groups on the sugar fragment in water, while the process occurs faster in basic buffer (Na2CO3, pH 12).52
Uranyl acetate and 200 mesh copper grids were purchased from Electron Microscopy Sciences (Hatfield, PA, USA).
Peptides were dissolved at 6.0 and 7.0 mM for BSP27–32 and β2m83–88, respectively, in 10 mM phosphate and with a peptide/metal complex molar ratio of 1:
5. At each time point, they were diluted at ∼1 mM. A drop of 10 μL of each sample was placed onto a formvar/carbon copper grid for 2 minutes, and washed two times in drops of distilled water. Negative staining was carried out in a drop of 100 μL of 2% (w/w) uranyl acetate aqueous solution for 2 minutes in the dark. After the incubation time, the excess of liquid was removed by touching the edge to a filter paper, and the grids were air-dried under hood. The imaging was performed by using a TEM Tecnai G2, 20_Thermofisher Company apparatus equipped with a CCD camera (Eagle-2HS), at 120 kV in a range of magnification between 8k× and 150k× (integration time: 1 s; image size 2048 × 2048).
The overlays of the ThT-fluorescence emission profiles of the His-amyloids in the presence or lack of Ru-compounds over time are reported in Fig. 2A and B.
ThT assays were performed at two different molar ratios of peptide to metal complex, 1:
1 and 1
:
5. By comparing peptides alone, BSP27–32 exhibited the typical amyloid profile with an increase of ThT emission in the first 15 min of analysis and then a slow decrease upon fibrillation.56
Conversely, the β2m83–88 peptide appeared already aggregated at t = 0 of analysis with a decrease of signal after 5 min.57
For both sequences, a decrease of the ThT signal is observed in the presence of Ru-compounds: the most potent inhibitor of aggregation appeared for Ru-Cym. Already at a 1:
1 ratio, it caused a neat suppression of fluorescence intensity. Meanwhile, both Ru-MBAG and Ru-Oxa at this ratio exhibited only a small reduction of signal, and required a higher ratio (1
:
5) to provide effects comparable to those of Ru-Cym. Control experiments, reported in Fig. S1,† allowed for the exclusion of any interference due to the interaction of Ru-complexes with ThT. In the case of BSP27–32, the presence of three aromatic residues, F29, F32 and Y28, acts as an additional probe for amyloid aggregation, following the intrinsic fluorescence at 303 nm (upon 275 nm-excitation) during time, as reported in Fig. 2C. BSP27–32 alone exhibits an increase of fluorescence intensity, as already observed for aromatic sequences, suggesting a prominent role in π-stacking during fibrillation.58
Conversely, the presence of Ru-compounds caused a decrease of fluorescence signal at the beginning of the analysis, corroborating the inhibitory effect on the aggregation. Control experiments, reported in Fig. S2,† indicate a negligible contribution of the emission of Ru compounds upon aromatic excitation.
![]() | ||
Fig. 3 ESI-MS spectra of mixtures of BSP27–32 (A0, A24 panels) and β2m83–88 (B0, B24 panels) with Ru-MBAG. Asterisks label peaks present in the spectra of Ru-MBAG alone. |
![]() | ||
Fig. 4 ESI-MS spectra of mixtures of BSP27–32 (A0, A24 panels) and β2m83–88 (B0, B24 panels) with Ru-Cym. Asterisks label peaks present in the spectra of Ru-Cym alone. |
![]() | ||
Fig. 5 ESI-MS spectra of mixtures of BSP27–32 (A0, A24 panels) and β2m83–88 (B0, B24 panels) with Ru-Oxa. Asterisks label peaks present in the spectra of Ru-Oxa alone. |
Time | Experimental m/z (z = +1) (Da) | Theoretical monoisotopic mass (Da) | Adducts | ||
---|---|---|---|---|---|
BSP27–32 + Ru-MBAG (MW: 1021.8 Da) | 0 h | 881.45 | 880.41 | BSP27–32 | |
1761.90 | 1760.82 | BSP27–32 dimer | |||
1782.65 | 1783.22 | BSP27–32 + Ru-MBAG − 2Cl− + 2H2O − 2Ac | 2 + 2H2O – 2Ac | ||
1824.67 | 1824.71 | BSP27–32 + Ru-MBAG − 1Cl− − 1Ac | 1 – 1Ac | ||
1886.71 | 1884.76 | BSP27–32 + Ru-MBAG − 1Cl− + 1H2O | 1 + H2O | ||
24 h | 881.45 | 880.41 | BSP27–32 | ||
1782.61 | 1783.22 | BSP27–32 + Ru-MBAG − 2Cl− + 2H2O − 2Ac | 2 + 2H2O – 2Ac | ||
1824.70 | 1824.71 | BSP27–32 + Ru-MBAG − 1Cl− − 1Ac | 1 – 1Ac | ||
1886.70 | 1884.76 | BSP27–32 + Ru-MBAG − 1Cl− + 1H2O | 1 + H2O | ||
β2m83–88 + Ru-MBAG (MW: 1021.8 Da) | 0 h | 711.41 | 710.35 | β2m83–88 | |
1421.79 | 1420.70 | β2m83–88 dimer | |||
1570.58 | 1571.11 | β2m83–88 + Ru-MBAG − 2Cl− + 2H2O − 3Ac | 2 + 2H2O – 3Ac | ||
1612.66 | 1613.16 | β2m83–88 + Ru-MBAG − 2Cl− + 2H2O − 2Ac | 2 + 2H2O – 2Ac | ||
1654.55 | 1654.65 | β2m83–88 + Ru-MBAG − 1Cl− − 1Ac | 1 − 1Ac | ||
1716.74 | 1714.70 | β2m83–88 + Ru-MBAG − 1Cl− + 1H2O | 1 + H2O | ||
24 h | 711.40 | 710.35 | β2m83–88 | ||
1570.60 | 1571.11 | β2m83–88 + Ru-MBAG − 2Cl− + 2H2O − 3Ac | 2 + 2H2O – 3Ac | ||
1612.63 | 1613.16 | β2m83–88 + Ru-MBAG − 2Cl− + 2H2O − 2Ac | 2 + 2H2O – 2Ac | ||
1714.59 | 1714.70 | β2m83–88 + Ru-MBAG − 1Cl− + 1H2O | 1 + H2O | ||
BSP27–32 + Ru-Cym (MW: 718.6 Da) | 0 h | 881.42 | 880.41 | BSP27–32 | |
1563.56 | 1563.56 | BSP27–32 + Ru-Cym – Cl− | 1 | ||
1581.56 | 1581.56 | BSP27–32 + Ru-Cym – Cl− + H2O | 1 + H2O | ||
24 h | 881.42 | 880.41 | BSP27–32 | ||
1480.54 | 1479.56 | BSP27–32 + Ru-Cym – Cl− − 2Ac | 1 – 2Ac | ||
1438.5 | 1437.56 | BSP27–32 + Ru-Cym – Cl− − 3Ac | 1 – 3Ac | ||
β2m83–88 + Ru-Cym (MW: 718.6 Da) | 0 h | 711.37 | 710.35 | β2m83–88 | |
1396.48 | 1393.50 | β2m83–88 + Ru-Cym – Cl− | 1 | ||
1310.30 | 1309.50 | β2m83–88 + Ru-Cym – Cl− – 2Ac | 1 – 2Ac | ||
24 h | 711.37 | 710.35 | β2m83–88 | ||
1310.3 | 1309.50 | β2m83–88 + Ru-Cym – Cl− – 2Ac | 1 – 2Ac | ||
1268.48 | 1267.50 | β2m83–88 + Ru-Cym – Cl− – 3Ac | 1 – 3Ac | ||
BSP27–32 + Ru-Oxa (MW: 735.7 Da) | 0 h | 881.46 | 880.41 | BSP27–32 | |
1761.90 | 1760.82 | BSP27–32 dimer | |||
1611.64 | 1611.57 | BSP27–32 + Ru-Oxa | |||
24 h | 881.45 | 880.41 | BSP27–32 | ||
1611.64 | 1611.57 | BSP27–32 + Ru-Oxa | |||
β2m83–88 + Ru-Oxa (MW: 735.7 Da) | 0 h | 711.40 | 710.35 | β2m83–88 | |
1421.80 | 1420.70 | β2m83–88 dimer | |||
1441.56 | 1441.51 | β2m83–88 + Ru-Oxa | |||
24 h | 711.39 | 710.35 | β2m83–88 | ||
1421.79 | 1420.70 | β2m83–88 dimer | |||
1441.37 | 1441.51 | β2m83–88 + Ru-Oxa |
![]() | ||
Fig. 6 Conformational analysis of β2m83-88. Overlay of CD spectra of β2m83-88 (400μM) alone (A) and with Ru-MBAG (B), Ru-Oxa (C) Ru-Cym (D), at 1![]() ![]() |
The presence of Ru-compounds did not drastically change the spectral profile over time (Fig. 6B–D). However, the presence of complexes allowed for a certain stability of the CD intensity as evaluated from Fig. S5,† in which the CD signals (at the minimum of each spectrum) at different times are reported. In particular, Ru-Cym, at higher times, stabilized the CD signal (and thus the monomeric state) more strongly with respect to other Ru-complexes. The CD profiles of the complexes alone (Fig. S6†) ensure no interference of the complexes on the peptide profile.
![]() | ||
Fig. 7 TEM analysis at t = 0 of the BSP27–32 peptide (A) alone, and in the presence of (B) Ru-Cym, (C) Ru-MBAG, and (D) Ru-Oxa. |
Conversely, the ESI data of Ru-Oxa indicated no ligand exchange. This behavior is likely due to the chelate stabilizing effect of oxalate with respect to monodentate chlorides that hampers the ligands’ exchange around the Ru center,64 as already observed during stability assays, allowing only electrostatic and/or hydrophobic interactions for the formation of adducts with peptides.
The choice of short His-amyloid peptides as model amyloids markedly simplified the synthesis and purification of the amyloidogenic systems, but simultaneously severely limited the conformational studies. Indeed, CD analysis allowed us to only assess a substantial stabilization of the monomeric form of the β2m83–88 peptide, especially in the presence of Ru-Cym. However, the conformational mechanisms cannot be detailed in-depth for such small peptides. Future investigations on larger polypeptides containing His-residues are required to translate into the observed inhibitory effects produced by the Ru-complexes on biological processes, and also to evaluate the inhibition of the amyloid cytotoxicity, considering that Ru-complexes were not toxic up to 100 μM in many cell lines.52
Finally, microscopy TEM investigations confirmed an immediate effect of Ru-Cym and Ru-MBAG on the amyloidogenicity of the BSP27–32 peptide, causing a neat dispersing effect on the typical fibers observable in their absence.
In conclusion, this study represents an interesting example of how in vitro SAR investigations of the MOAs of metallodrugs on amyloid systems can be of utmost importance for the employment of analogous glycoconjugate Ru-complexes as novel and selective drugs in neurodegenerative diseases.
Footnote |
† Electronic supplementary information (ESI) available: Overlay of ThT fluorescence emission intensity of Ru(II)-arene complexes; aromatic intrinsic fluorescence assay of Ru(II)-arene complexes; conformational analysis of Ru(II)-arene complexes; TEM analysis of β2m83–88 peptide alone and in presence of Ru(II)-arene complexes. See DOI: https://doi.org/10.1039/d3dt01110k |
This journal is © The Royal Society of Chemistry 2023 |